Sotrovimab Use in Young Pediatric Patients at High Risk of Progression to Severe COVID-19 Disease

J Pediatric Infect Dis Soc. 2023 Apr 28;12(4):242-245. doi: 10.1093/jpids/piad020.

Abstract

This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12-16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).

Keywords: COVID-19; SARS-CoV-2; children; monoclonal antibody; sotrovimab.

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antibodies, Neutralizing
  • COVID-19*
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Retrospective Studies

Substances

  • sotrovimab
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing